OTCMKTS:AYTU

Aytu Bioscience Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy AYTU

*Your capital is at risk

$2.23

+0.0800 (+3.72%)

At Close: Jul 31, 2026

Aytu Bioscience Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.49M and sold 1.63M AYTU shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	10.49M shares
● Sell	1.63M shares
98% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 31, 2024 Buy	Common Shares M-Exempt	Pyszczymuka Greg Chief Commercial Officer	Officer	208 Value: $354
Nov 11, 2024 Buy	Common Shares A-Award	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	14 000 Value: $24.8K
Nov 11, 2024 Buy	Common Shares	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	0 Value: $0
Nov 11, 2024 Buy	Restricted Stock Units	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	105 Value: $186
Nov 11, 2024 Buy	Employee Stock Option (Right to Buy)	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	5 791 Value: $23.2K
Nov 11, 2024 Buy	Employee Stock Option (Right to Buy)	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	5 000 Value: $9K
Nov 11, 2024 Buy	Employee Stock Option (Right to Buy)	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	5 000 Value: $9K
Nov 11, 2024 Buy	Employee Stock Option (Right to Buy)	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	5 000 Value: $9K
Nov 11, 2024 Buy	Employee Stock Option (Right to Buy)	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	5 000 Value: $9K
Nov 11, 2024 Buy	Employee Stock Option (Right to Buy)	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	5 791 Value: $23.2K
Nov 11, 2024 Buy	Restricted Stock Units	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	105 Value: $186
Nov 11, 2024 Buy	Common Shares	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	0 Value: $0
Nov 11, 2024 Buy	Common Shares A-Award	Selhorn Ryan J Chief Financial Officer	C-Suite Officer	14 000 Value: $24.8K
Nov 06, 2024 Buy	Common Shares A-Award	Dockery Carl Director	Director	1 500 Value: $3K
Nov 06, 2024 Buy	Common Shares A-Award	Donofrio John Jr. Director	Director	1 500 Value: $3K
Nov 06, 2024 Buy	Common Shares A-Award	Jain Abhinav Director	Director	1 500 Value: $3K
Nov 06, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Disbrow Joshua R. Chief Executive Officer	CEO / President	38 000 Value: $69.9K
Nov 06, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Disbrow Jarrett Chief Business Officer	Officer	7 000 Value: $12.9K
Nov 06, 2024 Buy	Common Shares A-Award	Liu Vivian H Director	Director	1 500 Value: $3K
Nov 06, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Pyszczymuka Greg Chief Commercial Officer	Officer	7 000 Value: $12.9K
Nov 06, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Pyszczymuka Greg Chief Commercial Officer	Officer	7 000 Value: $12.9K
Nov 06, 2024 Buy	Common Shares A-Award	Liu Vivian H Director	Director	1 500 Value: $3K
Nov 06, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Disbrow Jarrett Chief Business Officer	Officer	7 000 Value: $12.9K
Nov 06, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Disbrow Joshua R. Chief Executive Officer	CEO / President	38 000 Value: $69.9K
Nov 06, 2024 Buy	Common Shares A-Award	Jain Abhinav Director	Director	1 500 Value: $3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AYTU BIOSCIENCE

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the...

Read Full Profile Here